Combined treatment of giant-cell arteritis with methotrexate and prednisone. a randomized, double-blind, placebo-controlled trial.
about
Anti-TNF-alpha therapy and systemic vasculitis.Therapeutic effects of acetylsalicylic acid in giant cell arteritisGiant cell arteritis: managing the ophthalmic medical emergencyTherapy for giant cell arteritis: can we do better?AortitisAdjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis.Update on the management of giant cell arteritis.Estimating the Cost of Illness of Giant Cell Arteritis in the United States.The thromboembolic risk in giant cell arteritis: a critical review of the literature.A rare case of temporal arteritis with rheumatoid arthritis and interstitial lung disease mimicking pulpo-periodontal pathology.Diagnosis and treatment of cerebral vasculitis.[Current "off label use" of methotrexate for chronic inflammatory rheumatic diseases].Polymyalgia rheumatica and giant cell arteritis in older patients: diagnosis and pharmacological management.The treatment of giant cell arteritisNovel therapies in vasculitis.Polymyalgia rheumatica/temporal arteritis: recent advances.The value of glucocorticoid co-therapy in different rheumatic diseases--positive and adverse effectsAutoimmunity and geriatrics: clinical significance of autoimmune manifestations in the elderly.Recent advances in temporal arteritis.Giant cell arteritis: Current treatment and management.Disease Relapses among Patients with Giant Cell Arteritis: A Prospective, Longitudinal Cohort Study.Treatment of ischemic optic neuropathy.Relapses in patients with giant cell arteritis: prevalence, characteristics, and associated clinical findings in a longitudinally followed cohort of 106 patientsGiant cell arteritis: diagnosis and therapeutic management.EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis.Development of outcome measures for large-vessel vasculitis for use in clinical trials: opportunities, challenges, and research agenda.The Birmingham Vasculitis Activity Score as a Measure of Disease Activity in Patients with Giant Cell Arteritis.Giant cell arteritis: a systemic vascular disease.Neuro-ophthalmic complications in giant cell arteritis.Giant cell arteritis: an updated review.Steroid-sparing effect and toxicity of dapsone treatment in giant cell arteritis: A single-center, retrospective study of 70 patients.Biologic Therapy for the Treatment of Giant Cell Arteritis.Value of anti-infective chemoprophylaxis in primary systemic vasculitis: what is the evidence?Pharmacotherapy of vasculitis.Pyoderma Gangrenosum and Erythema Nodosum Revealing Takayasu's ArteritisHeadache and temporal arteritis: when to suspect and how to manage.Ultrasonographic resolution of the vessel wall oedema with modest clinical improvement in a large-vessel vasculitis patient treated with tocilizumab.Clinical features of polymyalgia rheumatica and giant cell arteritis.Tocilizumab: a new therapy for large vessel vasculitis.Clinical diagnosis and management of large vessel vasculitis: giant cell arteritis.
P2860
Q27687590-986478FA-FD6A-4FA2-9E31-D337F2734129Q28192358-2B95BAD7-7C90-4E5D-AD3C-592FEB3183EEQ28196369-B4B374E2-7E93-49EB-A1D8-868415BDFCB9Q28200578-6A833B79-76AA-4149-81B5-82F2B0544ABFQ28283283-403EC7AB-8F24-4654-9632-639201CF7726Q31120357-BEA08F7F-BB4D-4FEC-B72D-C5DF88819AFAQ33605954-E31A019D-5DD8-4B6E-94EE-920AF8479C1FQ33725515-141283C6-E81E-4BAF-B220-D365113B1A53Q33745753-765572EA-28E0-4FB6-9A26-857DA998D903Q34153209-75965603-9938-4072-AA20-B9B55458DDF8Q34156332-68B9A262-0CC2-4D2D-9224-184A228DD44DQ34160848-29E4D216-6EEC-41C0-9BD2-23F0A9FEDFDFQ34205665-44461173-656D-4821-A4EA-05AD4C94BB6EQ34461224-5B11F32C-E897-473E-823C-F44C12D37A4FQ34481560-DDD0384D-4E31-4AA3-B279-2CE458F5360CQ34499531-92A64E00-938C-4A0E-A967-205EECB27ED6Q34597321-1C2A26FC-E44F-451C-AB9F-2F907C31B0B7Q35135284-F165E851-1602-4855-8209-9FF0F799C7C9Q35163741-D4B8DAE1-908C-4A1A-A8DC-EE902851FB41Q35746677-71EAFA6D-7E53-4D69-84E0-76A731C526BAQ35861674-1996D88A-BE92-4CC5-A0E3-5A558D57DA0AQ35932508-B55CABAD-E1CB-46C9-8E76-59C093BC55DEQ36150929-6A991CBE-83D4-4D6A-A961-9E832757EFCDQ36535227-9016BA04-6377-4F85-A34D-FFFE253E6720Q36684589-979664A3-82DE-4606-B9EB-BD2317A7466AQ36843077-9391E205-BFC2-4950-8027-231072330B4FQ36963349-01F6520E-5A66-47BB-BBD9-672D7B972D49Q37204521-C591FCF9-EE27-49BC-A507-A9A66795DB43Q37208972-9A236E60-2EC8-4FA9-9475-ACB6A7B15AA7Q37304297-F8C8FC39-F2FD-4E32-910E-03915DCCEEE3Q37364920-0FFC9F44-3BD0-4091-B0E2-7ACF0015C65AQ37439687-206B5737-CB6D-4FEC-B222-B1F6E4934857Q37453850-45D0AFE6-1F8C-4833-A51B-B39DDA03B14FQ37483910-2937D74B-CB4A-443B-87B8-82E5E93C13A0Q37563007-40270EFD-EFF6-4DA8-88F1-53DA565E389CQ38007105-5D3DC673-1BB3-4F03-A585-DB0E169FB73DQ38015743-4D84D909-66AF-4953-8CEA-A6F2C39957DEQ38028863-7EAA5264-CF70-4E99-84E9-B5C64DBEAF13Q38129269-61E499D6-BE2D-4CAC-A135-1BE3EA8905B4Q38217341-DCE728BF-44ED-4FBA-8904-DF79E8999DB7
P2860
Combined treatment of giant-cell arteritis with methotrexate and prednisone. a randomized, double-blind, placebo-controlled trial.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Combined treatment of giant-ce ...... ind, placebo-controlled trial.
@ast
Combined treatment of giant-ce ...... ind, placebo-controlled trial.
@en
type
label
Combined treatment of giant-ce ...... ind, placebo-controlled trial.
@ast
Combined treatment of giant-ce ...... ind, placebo-controlled trial.
@en
prefLabel
Combined treatment of giant-ce ...... ind, placebo-controlled trial.
@ast
Combined treatment of giant-ce ...... ind, placebo-controlled trial.
@en
P2093
P1476
Combined treatment of giant-ce ...... ind, placebo-controlled trial.
@en
P2093
Fernández-Gutiérrez B
Hernández-García C
P304
P356
10.7326/0003-4819-134-2-200101160-00010
P407
P577
2001-01-01T00:00:00Z